Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MSCI Canada (TSX) — how do they compare? Charles River Laboratories Intl. Inc trades at $284.91 (market cap $13.46B), while iShares MSCI Canada (TSX) trades at $61.73. Which is the better fit depends on your goals.
| CRL | EWC | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $282.00 | $61.51 |
52-Week Low | $145.57 | $47.00 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
EWC trades at $61.81, up 0.5% on the day, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The ETF shows strong performance in 2026 with double-digit returns, though it trails the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, but key exclusions may limit material impact.
Outlook remains cautiously optimistic due to Canada's economic resilience and active ETF market growth. Risks include trade war escalation and commodity price volatility, but analyst sentiment supports bullish positioning for diversified exposure to Canadian equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
